setanaxib
Small moleculeexperimental
Setanaxib is an experimental orally bioavailable dual inhibitor of NADPH oxidase isoforms NOX4 and NOX1. Setanaxib is a member of the pyrazolopyridine dione chemical series. The compound is the only specific NOX inhibitor that has entered into clinical trials. — Wikipedia
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 5, 2020 (NCT04327089)
Timeline
Indications
Mechanism of action
- Ecto-NOX disulfide-thiol exchanger 2INHIBITOR
ENOX2 inhibitor
- NADPH oxidase 1INHIBITOR
NADPH oxidase 1 inhibitor
- NADPH oxidase 4INHIBITOR
NADPH oxidase 4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)c1cccc(-c2c3c(=O)n(-c4ccccc4Cl)[nH]c3cc(=O)n2C)c1- Mol. weight
- 394.86 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSetanaxib ↗
- ChEMBLCHEMBL4303187 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06274489 | Phase 1/Phase 2 (Phase 2) | Nov 27, 2023 | Calliditas Therapeutics |
| NCT05323656 | Phase 2 | Apr 6, 2022 | Calliditas Therapeutics |
| NCT05014672 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2021 | Genkyotex Innovation SAS |
| NCT04327089 | Phase 1 | May 5, 2020 | Genkyotex Innovation SAS |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Calliditas Therapeutics | For profit | 2 | 2 | 1 | 2022 |
| Genkyotex Innovation SAS | For profit | 2 | 2 | 2 | 2020 |
2 organizations
Page 1 / 1